MTNB.US Matinas BioPharma Holdings Inc

Healthcare Biotechnology USA Stocks
0.9000 USD
Close of Nov 15, 2026
0.8071 17.40
Market cap
USD 882K
P/E
-
P/B
0.49x
ROE
-360.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is MTNB.US undervalued?

Graham number

The Graham number of Matinas BioPharma Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Matinas BioPharma Holdings Inc fundamental analysis

No fundamental analysis for Matinas BioPharma Holdings Inc yet.

Matinas BioPharma Holdings Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Matinas BioPharma Holdings Inc

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for…

Full company profile